Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand (NASDAQ:DERM)


Revenue and margin growth are primarily driven by the successful launch and increasing sales of Emrosi, improvements in gross margin, expansion of payer coverage, and disciplined cost management despite ongoing competitive pressure on legacy products.



Source link

Which Lana Del Rey Album Matches You Best?

21 Savage Seemingly Reacts To Latto’s Pregnancy Announcement

Leave a Reply

Your email address will not be published. Required fields are marked *